Voss Capital LP Makes New Investment in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)

Voss Capital LP bought a new stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 122,361 shares of the company’s stock, valued at approximately $1,490,000. Voss Capital LP owned approximately 0.21% of Cullinan Therapeutics as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Tower Research Capital LLC TRC grew its stake in Cullinan Therapeutics by 411.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,800 shares of the company’s stock worth $107,000 after buying an additional 7,079 shares during the last quarter. MetLife Investment Management LLC increased its holdings in Cullinan Therapeutics by 7.4% during the 4th quarter. MetLife Investment Management LLC now owns 32,058 shares of the company’s stock valued at $390,000 after purchasing an additional 2,217 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Cullinan Therapeutics by 28.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,318,372 shares of the company’s stock valued at $16,058,000 after purchasing an additional 295,467 shares during the last quarter. Jump Financial LLC grew its holdings in shares of Cullinan Therapeutics by 130.7% during the fourth quarter. Jump Financial LLC now owns 66,135 shares of the company’s stock worth $806,000 after purchasing an additional 37,469 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Cullinan Therapeutics in the fourth quarter valued at $529,000. Institutional investors own 86.31% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on CGEM shares. Morgan Stanley reissued an “overweight” rating and set a $35.00 price objective (down previously from $38.00) on shares of Cullinan Therapeutics in a report on Friday, March 7th. HC Wainwright reissued a “buy” rating and issued a $33.00 price target on shares of Cullinan Therapeutics in a report on Wednesday, April 16th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $34.80.

Insider Buying and Selling

In other Cullinan Therapeutics news, CEO Nadim Ahmed sold 12,529 shares of the business’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $8.53, for a total value of $106,872.37. Following the completion of the transaction, the chief executive officer now directly owns 430,621 shares of the company’s stock, valued at approximately $3,673,197.13. The trade was a 2.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jeffrey Alan Jones sold 4,895 shares of Cullinan Therapeutics stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $8.53, for a total value of $41,754.35. Following the transaction, the insider now owns 174,164 shares in the company, valued at $1,485,618.92. This trade represents a 2.73 % decrease in their position. The disclosure for this sale can be found here. 6.07% of the stock is owned by insiders.

Cullinan Therapeutics Price Performance

Shares of NASDAQ CGEM opened at $7.89 on Monday. Cullinan Therapeutics, Inc. has a fifty-two week low of $6.85 and a fifty-two week high of $30.19. The firm has a market capitalization of $461.67 million, a P/E ratio of -2.78 and a beta of -0.05. The company’s 50 day simple moving average is $8.36 and its 200 day simple moving average is $11.45.

Cullinan Therapeutics (NASDAQ:CGEM) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.02. Sell-side analysts expect that Cullinan Therapeutics, Inc. will post -3.04 EPS for the current fiscal year.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.